Company Filing History:
Years Active: 2014
Title: Marie P. Piechocki: Innovator in Cancer Therapeutics
Introduction
Marie P. Piechocki is a notable inventor based in Fraser, MI (US). She has made significant contributions to the field of cancer therapeutics through her innovative research and development of vaccine compositions. Her work focuses on inducing the production of antibodies that target specific cellular death receptors, which is crucial in the fight against cancer.
Latest Patents
Marie P. Piechocki holds a patent for a vaccine targeting the cellular death receptor DR5. This invention provides therapeutics and methods to induce a mammalian host, including humans, to produce antibodies that agonize death receptors. This process leads to the apoptotic death of target cells within the host's body. The vaccine compositions include genetic vaccines encoding death receptor antigens of the tumor necrosis factor receptor family. Additionally, the invention offers means and methods for overcoming host immunological tolerance to death receptors. These vaccines are beneficial against cancer cells and other death receptor-bearing target cells, and they can be utilized in both therapeutic and prophylactic settings. Furthermore, the vaccines serve as useful tools for diagnostic testing of the immunocompetence of a host.
Career Highlights
Marie P. Piechocki is affiliated with Wayne State University, where she continues her research and development efforts. Her work has garnered attention for its potential impact on cancer treatment and immunology.
Collaborations
Marie has collaborated with esteemed colleagues such as Wei-Zen Wei and Gen Sheng Wu, contributing to the advancement of her research and the development of innovative therapeutic solutions.
Conclusion
Marie P. Piechocki's contributions to cancer therapeutics through her patented vaccine targeting cellular death receptor DR5 highlight her role as a leading innovator in the field. Her work not only advances scientific understanding but also offers hope for improved cancer treatments.